Tajikistan Support for Inactivated Polio Vaccine (IPV)
This Decision Letter sets out the Terms of a Programme

1. **Country:** Tajikistan

2. **Grant Number:** 1518-TJK-25b-X / 15-TJK-08h-Y

3. **Date of Decision Letter:** 2 March 2015

4. **Date of the Partnership Framework Agreement:** 7 November 2012

5. **Programme Title:** NVS, IPV Routine

6. **Vaccine type:** Inactivated Polio Vaccine (IPV)

7. **Requested product presentation and formulation of vaccine**: Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID

8. **Programme Duration**: 2015 - 2018

9. **Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):**

   Please note that endorsed or approved amounts for 2018 will be communicated in due course, taking into account updated information on country requirements and following Gavi’s review and approval processes.

<table>
<thead>
<tr>
<th>Programme Budget (US$)</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>Total²</th>
</tr>
</thead>
<tbody>
<tr>
<td>US$254,500</td>
<td>US$714,500</td>
<td>US$521,000</td>
<td>US$1,490,000</td>
<td></td>
</tr>
</tbody>
</table>

10. **Vaccine Introduction Grant:** US$222,000 already disbursed in 2014.

11. **Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):**³ The Annual Amounts for 2015 and 2016 have been amended.

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds in each year</th>
<th>2015</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of IPV vaccines doses</td>
<td>123,800</td>
<td>347,900</td>
</tr>
<tr>
<td>Number of AD syringes</td>
<td>119,600</td>
<td>332,700</td>
</tr>
<tr>
<td>Number of safety boxes</td>
<td>1,325</td>
<td>3,675</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>US$254,500</td>
<td>US$714,500</td>
</tr>
</tbody>
</table>

12. **Procurement agency:** UNICEF

13. **Self-procurement:** Not applicable

14. **Co-financing obligations:**

   Gavi’s usual co-financing requirements do not apply to IPV. However, Tajikistan is encouraged to contribute to vaccine and/or supply costs for IPV.

---

¹ Please refer to section 18 for additional information on IPV presentation.
² This is the entire duration of the programme.
³ This is the total amount endorsed by Gavi for 2015 to 2017.
⁴ This is the amount that Gavi has approved.
15. **Operational support for campaigns:** Not applicable

16. The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts:

<table>
<thead>
<tr>
<th>Reports, documents and other deliverables</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual Progress Report or equivalent</td>
<td>To be agreed with Gavi Secretariat</td>
</tr>
</tbody>
</table>

17. **Financial Clarifications:** Not applicable

18. **Other conditions:**

Please provide copy of insurance policy certifying that vaccines and devices are insured as per Partnership Framework Agreement requirement.

If Tajikistan envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Tajikistan.

Signed by,

**On behalf of Gavi**

Hind Khatib-Othman
Managing Director, Country Programmes
2 March 2015